Study of JK07 in Patients With Chronic Heart Failure

Inclusion Criteria:

• Participants with New York Heart Association (NYHA) Class II-III.

• Cohort 1 - Left Ventricular Ejection Fraction (LVEF) ≤ 40%.

• Cohort 2 - Left Ventricular Ejection Fraction (LVEF) >40% and ≤ 65%, elevatedN-terminal pro B-type natriuretic peptide (NT-proBNP) ≥ 600pg/mL and atrialfibrillation/flutter.

• Stable heart failure and on optimal medical therapy.

• Screening hemoglobin ≥ 9.0 g/dL.

Exclusion Criteria:

• Uncontrolled hypertension.

• Sustained systolic Blood Pressure (BP) < 90 mmHg and/or diastolic BP < 50 mmHg on 2consecutive (duplicate seated) readings at screening.

• Heart failure due to hypertrophic cardiomyopathy, restrictive and/or infiltrativecardiomyopathy, arrhythmogenic right ventricular dysplasia, Fabry disease, or Noonansyndrome with LV hypertrophy or a positive serum immunofixation result.

• Diagnosis of stress-induced (Takotsubo) cardiomyopathy, myocarditis, or peripartumcardiomyopathy.

• Diagnosis of chemotherapy- or radiation-induced cardiomyopathy.

• Diagnosed with stroke or Transient Ischemic Attack (TIA) within 12 weeks ofscreening.

• History of syncope within the last 12 weeks prior to screening or sustainedventricular tachycardia without an implantable cardioverter-defibrillator.

• Moderate or severe aortic and/or mitral valve stenosis.

• Medically documented unstable angina, acute coronary syndrome (e.g., myocardialinfarction, troponin-positive with symptoms of angina or unstable angina) within thelast 8 weeks prior to start of screening.

• Medically documented ST-elevation myocardial infarction within 12 weeks ofscreening.

• Any tachycardia (inclusive of Atrial Fibrillation (AF) or atrial flutter) with aresting ventricular rate > 110 beats per minute at screening.

• For participants with a history of AF or atrial flutter, not on adequateanticoagulant therapy via non-vitamin K oral anticoagulants or warfarin if theCHA2DS2-VASc score is ≥ 2 in men or ≥ 3 in women or per local guidelines.Percutaneous occlusion of the left atrial appendage alone is not adequate.

• AF ablation within the last 12 weeks prior to screening or planned during the studyduration.

• Symptomatic bradycardia or second (Mobitz Type II)- or third-degree heart blockwithout a pacemaker.

• Cardiac surgery, coronary artery revascularization or indication for coronary arteryrevascularization, percutaneous coronary intervention, valve repair/replacement orvalvuloplasty within 12 weeks prior to screening.

• Implantation of a Cardiac Resynchronization Therapy (CRT) device within 12 weeksprior to screening, or intent to implant a CRT device during the course of thestudy.

• Previous cardiac transplantation, or any use of mechanical circulatory support orsimilar device, or implantation expected after randomization.

• Receiving mechanical hemodynamic support or invasive mechanical ventilation withinthe last 8 weeks prior to screening.

• Receiving Intravenous (IV) inotropes or IV vasopressors within the last 8 weeksprior to screening.

• Receiving IV vasodilators within the last 4 weeks prior to screening.

• Receiving noninvasive mechanical ventilation within the last 4 weeks prior toscreening. The use of noninvasive ventilation for sleep disordered breathing ispermitted.